Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 111,241

Document Document Title
WO/2016/016382A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO/2016/016381A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO/2016/015378A1
Usage of a protein kinase inhibitor in preparing a neural cell from a differentiated non-neural cell is provided.  
WO/2016/019312A3
Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.  
WO/2016/016292A1
The present invention relates to compounds of formula (I), wherein L is a bond, -C(O)NH-, -NHC(O)-, -CH2NHC(O)-, CH2C(O)NH-, -CH2NH-, -NH- or -NHC(O)NH-; R1 is hydrogen, lower alkyl, halogen, lower alkoxy-alkyl, lower alkoxy substituted ...  
WO/2016/018178A4
The invention relates to pharmaceutics and para-pharmaceutics, and more particularly to agents for the cessation of smoking. Proposed is a complex anti-nicotine agent, containing nicotine or a nicotine-like alkaloid and the amino acids t...  
WO/2016/016383A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO/2016/018117A1
The present invention relates to an FK506 derivative which has no immunosuppressive activity but maintains nerve regeneration activity, a preparation method therefor, and a pharmaceutical composition comprising the same for preventing or...  
WO/2016/016380A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO/2016/016162A1
The present invention relates to a compound of formula (I), wherein L is –C(O)NH-, -NHC(O)-, -S(O)2NH-, -NH- or -NHC(O)NH-; Ar is phenyl, benzyl, naphthyl or heteroaryl, selected from the group consisting of pyridinyl, pyrazolyl, pyrim...  
WO/2016/016790A1
The present invention relates to an ester of a phospholipid with conjugated linoleic acid for use in the therapeutic treatment of or as a food supplement for psychiatric disorders with neuroinflammatory and neurodegenerative basis, such ...  
WO/2016/017826A1
Provided are: a xanthine oxidase inhibitor containing, as an active ingredient, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof; an agent to improve endothelial function; and an agent suitable for the ...  
WO/2016/014982A1
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, parti...  
WO/2016/012384A1
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2016/011943A1
The present invention relates to a new benzodiazepine derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and use thereof. The benzodiazepine derivative and the pharmaceutically acceptable salt thereof of t...  
WO/2016/013049A1
A packaged acetaminophen injection solution preparation (1) comprises an oxygen-impermeable packaging container (2) and an acetaminophen injection solution preparation including acetaminophen aqueous solution of pH 4 to 8 containing acet...  
WO/2016/014117A1
The present invention is focused primarily toward pro re nata ("as needed") treatments for the symptoms of panic and anxiety. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one ...  
WO/2016/012896A1
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R3, and b are as defined herein. The inventions also directed to pharmaceutical compositions comp...  
WO/2016/011931A1
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for e...  
WO/2016/014908A1
Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, includin...  
WO/2016/012422A1
The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pre...  
WO/2016/012916A1
The present invention relates to novel compounds that inhibit Lp‐PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases or disorders associated with the activity of...  
WO/2016/012917A1
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases or disorders associated with the activity of L...  
WO/2016/014847A1
Compounds are provided which bind to an allosteric site on the mammalian alpha-7 nicotinic acetylcholine receptor (alpha-7 nAChR) and act as positive allosteric modulators with or without allosteric agonist activity. The compounds are us...  
WO/2016/012657A1
The present invention relates to medicaments based on oligomeric forms of 3- hydroxybutyrate, particularly 3-hydroxybutyrate methyl ester dimer (1) and trimer (2), especially for use in treating, preventing and/or inhibiting development ...  
WO/2016/011535A1
Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations compr...  
WO/2016/013617A1
The present invention addresses the problem of providing a brain function improving agent and a prophylactic or therapeutic agent for cognitive dysfunction, each of which does not induce diarrhea and/or nausea, has a form that is easy to...  
WO/2016/011487A1
The present invention relates to polypeptides of SEQ ID NO: 1 (as well as biologically active derivatives thereof), that bind specifically to BACE1 and/or IL-4Rα. Compositions and methods incorporating the polypeptide of SEQ ID NO: 1 (o...  
WO/2016/011930A1
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for e...  
WO/2016/011979A1
The present invention relates to a 2,4-Disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, a preparation method and a medicinal use thereof. In particular, the present invention discloses a compound of formula (I) or a pharmaceutically...  
WO/2016/014242A1
Described are compositions that may be orally administered that comprise a bioreversible derivative of hydroxy N-substituted-2-aminotetralin or an enantiomer or salt or prodrug thereof, and a pharmaceutically acceptable carrier suitable ...  
WO/2016/010809A1
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease slates, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is g...  
WO/2016/008966A1
The present invention relates to methods for treating neuromuscular junction-related diseases. In particular, the present invention relates to a method of treating a neuromuscular junction-related disease in a subject in need thereof com...  
WO/2016/009065A3
The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R" does not exist when Q is O; R' independently represent a hydrogen ...  
WO/2016/009341A1
The present invention provides thioredoxin (TRX) mimetic prodrugs, more particularly, derivatives or analogues of the amino acid sequence Cys-Pro-Cys or A1 -Cys- A2 -Pro-A3 -Cys-A4 wherein A1 to A4 each independently is either absent or ...  
WO/2016/008650A1
The present invention relates to the use of a combination of valerian root extract and lavender oil for the treatment of sleep disorders, and to a combination drug comprising valerian root extract and lavender oil.  
WO/2016/009297A1
The present invention provides, in part, compounds of Formula I: (I) N-oxides thereof, and pharmaceutically acceptable salts of the compounds or N-oxides; processes for the preparation of; intermediates used in the preparation of; and co...  
WO/2016/009430A1
An agent that reduces type I IFN activity at the choroid plexus or within the CNS for use in treating a disease, disorder, condition or injury of the CNS is provided.  
WO/2016/009021A1
The present invention relates to a dosage form which comprises two units A and B the composition of which is adapted to the circadian rhythm such that the dosage form can contribute to a perceptible increase in well-being. The dosage for...  
WO/2016/011088A2
The present disclosure relates to novel compounds and pharmaceutical compositions thereof which are useful as inhibitors of proteasomes. The compounds provided herein have improved proteasome potency and selectivity, and increased aqueou...  
WO/2016/008047A1
Pharmaceutical compositions and methods for the treatment or prophylaxis of Amyloid beta-related disorders such as Alzheimer's disease in a subject are provided by vaccination using a cyclic peptide or antibody to the SNK epitope in the ...  
WO/2016/011037A1
The unique polymeric OGF and enkephalin peptide conjugates with large size polymer attached at the C-terminus through hydrolysable linkage enhancing therapeutic properties of OGF and enkephalin peptides.  
WO/2016/009066A1
The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition comprising said compound ...  
WO/2016/010108A1
A compound represented by formula (I) [in the formula: (1) represents (2), (3), etc.; R2a represents optionally substituted alkyl, etc.; R2b, R3a, R3b, R4a, R4b, R5a and R5b independently represent a hydrogen atom, etc.; and R1 represent...  
WO/2016/011270A2  
WO/2016/010092A1
Provided are: a compound that is useful as an amyloid oxidation catalyst which can be applied inside a living body and can be applied not only to Aβ peptides but also to other amyloids; and an amyloid-related preventive or therapeutic d...  
WO/2016/007729A1
Provided herein are drug products comprising a combination of an opioid receptor agonist and an opioid receptor agonists, including co-packaged drug products comprising an opioid receptor agonist and an opioid receptor antagonist in a de...  
WO/2016/007630A1
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.  
WO/2016/005419A1
The present invention is directed to new compounds of formula (I) selectively binding the cannabinoid 2 receptor. In addition, the invention relates to the use of said compounds for determining cannabinoid receptor 2 (CB2)-selective rece...  
WO/2016/006593A1
Provided are an amyloid fibril formation inhibitor and a therapeutic or prophylactic drug for neurodegenerative diseases, said inhibitor and drug comprising a compound represented by general formula (I), a pharmaceutically acceptable sal...  

Matches 451 - 500 out of 111,241